Elai Davicioni

Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company?s differentiated approach measures the biological activity of a patient?s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient?s tumor, enabling physicians to select an optimal therapy. The firm?s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA.

GenomeDx, Inc. operates as a genomic information company developing solutions for prostate cancer treatment and the management of other urologic cancers. It offers Decipher and Guidance test. The company is headquartered in San Diego, CA.

Compugen, Inc. provides technology solutions and services. Its services include managed, professional, support and maintenance, asset disposal and recycling, hardware and software management and financing services. The company was founded by Harry Zarek in 1981 and is headquartered in Richmond Hill, Canada.

Genome Diagnostics, Inc. develops products for the medical diagnostics and personalized medicine markets. It focuses on harnessing the wealth of information encoded in the human genome to better address acute medical needs in oncology. The company was founded in 2007 and is headquartered in Pasadena, CA.